The crown jewel in EPCT is their Apoptosis screening technology. Every major company has their eye on this company. Question is, when will jack throw in the towel. I have a feeling the reason MYGN is not talking about Azixa is because this is a whole new class of drugs and they are worried about a bigger player getting involved in the game!
As a matter of fact EPCT's anti-cancer screening apoptosis platform ASAP represents an own and significant value. This kind of discovery technologies belongs to the most valuable assets of a pharma company. Such platforms speed up development and can reduce the expensive risk of needless clinical trials. "Big pharma" already made many attempts, also paid big money, to get involved or to acquire such kind techniques, however, "big pharma" also means a low speed to grasp and to transform progress.